Research Topics
| ELIZABETH MARION JAFFEESummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Cytokine gene-modified cell-based cancer vaccinesR Todd Reilly
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Methods Mol Med 69:233-57. 2002- Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activationE M Jaffee
Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
J Clin Oncol 19:145-56. 2001..To determine its safety and ability to induce antitumor immune responses, we conducted a phase I trial in patients with surgically resected adenocarcinoma of the pancreas... - Chemotherapy: friend or foe to cancer vaccines?L A Emens
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
Curr Opin Mol Ther 3:77-84. 2001..These interactions will require thorough preclinical evaluation to maximize the clinical impact of this type of therapeutic cancer vaccine... - Focus on pancreas cancerElizabeth M Jaffee
The Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
Cancer Cell 2:25-8. 2002 
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceLukas W Pfannenstiel
Department of Oncology, Sidney Kimmel Cancer Center, Division of Immunology, Johns Hopkins University, USA
Cell Immunol 263:79-87. 2010..Finally, PTX treatment results in enhanced antigen-specific, IFN-gamma-secreting CD8(+) T cells in vivo. Thus, administration of PTX with a tumor vaccine improves T cell priming through enhanced maturation of DC...- HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic miceMatthew E Wolpoe
Department of Otolaryngology Head and Neck Surgery, Graduate Program in Immunology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
J Immunol 171:2161-9. 2003..Collectively, these observations suggest that similarly increased efficacy could be obtained by combining neu-targeted vaccination and neu-specific Abs such as trastuzumab (Herceptin) in patients with neu-expressing cancers... - Cytokine modified tumor vaccinesTodd D Armstrong
Bunting-Blaustein Cancer Research Building, Room 4M86, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA
Surg Oncol Clin N Am 11:681-96. 2002..Most clinical trials using genetically modified tumor vaccines have shown immunological responses (DTH), but few clinical responses. Certain chemotherapeutic agents may enhance the immune effects of genetically modified tumor vaccines... - Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCsPeter S Kim
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 4M86, Baltimore, Maryland 21231, USA
J Clin Invest 118:1700-11. 2008..This multimodality attack on the same tumor antigen may have the potential to overcome tolerance to self antigens and weaken the immunosuppressive networks within the tumor microenvironment... - Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens
Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Clin Oncol 27:5911-8. 2009..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer... - Cancer vaccines in combination with multimodality therapyLeisha A Emens
The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90 Baltimore, Maryland 21231-1000, USA
Cancer Treat Res 123:227-45. 2005 - Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinomaIhid C Leao
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Clin Transl Sci 1:228-39. 2008.... - Leveraging the activity of tumor vaccines with cytotoxic chemotherapyLeisha A Emens
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
Cancer Res 65:8059-64. 2005.... - Cellular vaccine approachesDung T Le
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St, Bunting Blaustein Cancer Research Building, Room 407, Baltimore, MD 21231, USA
Cancer J 16:304-10. 2010.... - Immunotherapy for pancreatic cancer - science driving clinical progressDan Laheru
Department of Medical Oncology, Room G89, Baltimore, Maryland 21231-1000, USA
Nat Rev Cancer 5:459-67. 2005..Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials... - Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune responseAnne M Ercolini
Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Exp Med 201:1591-602. 2005.... - Augmenting the potency of breast cancer vaccines: combined modality immunotherapyLeisha A Emens
Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
Breast Dis 20:13-24. 2004..Combined modality immunotherapies should maximize the potency of the antitumor immune response, thereby improving the outcome of breast cancer therapy... - To live or not to live: that depends on GAGE?Leisha A Emens
Departments of Oncology, The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
Cancer Biol Ther 1:388-90. 2002 - Toward a breast cancer vaccine: work in progressLeisha A Emens
Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Oncology (Williston Park) 17:1200-11; discussion 1214, 1217-8. 2003.... - Cancer vaccines: an old idea comes of ageLeisha A Emens
Departments of Oncology, The Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland 21231 1000, USA
Cancer Biol Ther 2:S161-8. 2003.... - Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccineXianzheng Zhou
Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Cancer Res 65:1079-88. 2005.... - Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccineDan Laheru
The Sidney Kimmel Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Methods Mol Med 103:299-327. 2005..Without knowledge of specific antigen targets, the whole tumor cell represents the best source of immunizing antigens. This chapter will focus on the development of whole tumor cell vaccine strategies for pancreas cancer... - Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunologyDan A Laheru
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Bunting-Blaustein Cancer Research Building, Room 4M07, 1650 Orleans Street, Baltimore, MD 21231, USA
Mol Cancer Ther 4:1645-52. 2005..We outline here a paradigm for early-stage clinical development of immunotherapy combinations that use vaccines to drive tumor antigen-specific responses while simultaneously targeting immune regulatory pathways... - Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigensJosef Mautner
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Int J Cancer 115:752-9. 2005..These experiments show that a dual Th1/Th2, MHC class II-restricted T-helper-cell response against diverse shared tumor antigens has been elicited in this patient... 
Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus settingTomoharu Miyashita
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Dig Dis Sci 53:2858-67. 2008..We developed and evaluated a GM-CSF whole-cell tumor vaccine for esophageal cancer...- A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanismElizabeth A Manning
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Clin Cancer Res 13:3951-9. 2007.... - OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigenSatoshi Murata
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Immunol 176:974-83. 2006..These studies highlight the increased efficacy of OX40 costimulation when combined with a GM-CSF-secreting vaccine, and define a new role for OX40 costimulation of CD8+ T cells in overcoming tolerance and boosting antitumor immunity... - Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patientsAmy Morck Thomas
Department of Oncology, The Sidney Kimmel Cancer Center at Johns Hopkins, The Bunting-Blaustein Cancer Research Bldg, Rm. 4M07, 1650 Orleans St, Baltimore, MD 21231, USA
J Exp Med 200:297-306. 2004..These results provide the first direct evidence that CD8 T cell responses can be generated via cross-presentation by an immunotherapy approach designed to recruit APCs to the vaccination site... - Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cellsXianzheng Zhou
Division of Immunology and Hematppoiesis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Hum Gene Ther 14:1089-105. 2003..These results will have significant implications for the study of T-cell biology and for the improvement of clinical gene therapies of acquired immune deficiency syndrome (AIDS) and cancer... - Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus settingTomoharu Miyashita
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
J Gastrointest Surg 12:2-7; discussion 7-9. 2008..We developed a granulocyte-macrophage-colony-stimulating factor (GM-CSF) tumor vaccine for esophageal cancer. We evaluated the effectiveness of the vaccine as a prevention option in a surgical reflux rat model of esophageal cancer... - Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility geneSian Jones
Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Baltimore, MD 21231, USA
Science 324:217. 2009..These results illustrate that complete, unbiased sequencing of protein-coding genes can lead to the identification of a gene responsible for a hereditary disease... - SMAD4 gene mutations are associated with poor prognosis in pancreatic cancerAmanda Blackford
Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
Clin Cancer Res 15:4674-9. 2009..Recently, the majority of protein coding genes were sequenced in a collection of pancreatic cancers, providing an unprecedented opportunity to identify genetic markers of prognosis for patients with adenocarcinoma of the pancreas... - Genetic mutations associated with cigarette smoking in pancreatic cancerAmanda Blackford
Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
Cancer Res 69:3681-8. 2009..Pancreatic carcinomas from cigarette smokers harbor more mutations than do carcinomas from never smokers. The types and patterns of these mutations provide insight into the mechanisms by which cigarette smoking causes pancreatic cancer... - Core signaling pathways in human pancreatic cancers revealed by global genomic analysesSian Jones
Sol Goldman Pancreatic Cancer Research Center, Ludwig Center and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
Science 321:1801-6. 2008..Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis... - Pancreatic cancerTheresa Pluth Yeo
Departments of Surgery, Oncology, Pathology and Medicine Johns Hopkins Medical Institutions Baltimore, Maryland, USA
Curr Probl Cancer 26:176-275. 2002 - Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan
Morphotek Inc, 210 Welsh Pool Road, Exton, PA, USA
Cancer Immun 7:20. 2007..We have in fact initiated a Phase I clinical study enrolling patients with mesothelin-positive pancreatic, mesothelioma, non-small cell lung and ovarian cancers... - Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouseReshma Singh
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Immunol 175:3663-73. 2005..monocytogenes-based HER-2/neu vaccines in a murine model of breast cancer and also that the immunogenicity of self-Ags can be increased by fusion to LLO and delivery by L. monocytogenes revealing subdominant epitopes... - Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivoStephan R Scheffer
Department of Gastroenterology, Medizinische Hochschule Hannover, Hannover, Germany
Int J Cancer 103:205-11. 2003..In contrast, necrotic cell vaccines attracted a strong local macrophage response. Our data clearly demonstrate that only apoptotic tumor cell vaccines induce a potent antitumor immune response... - Cancer immunologists and cancer biologists: why we didn't talk then but need to nowGeorge C Prendergast
Cancer Cell Signaling Laboratory, Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA
Cancer Res 67:3500-4. 2007.... - Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanismsSara Gandini
Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
Cancer Epidemiol Biomarkers Prev 14:1908-16. 2005..The hyperactive immune system of allergic individuals may, therefore, in some way lead to increased surveillance and protect against pancreatic cancer development... - Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type miceTimothy P Moran
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA
Vaccine 25:6604-12. 2007..These findings provide the rationale for future evaluation of VRP-DC vaccines in the clinical setting...
Research Grants
- Chemotherapy plus vaccine for metastatic breast cancerElizabeth Jaffee; Fiscal Year: 2005..In addition, characterization of breast tumor antigens may lead to the development of recombinant vaccines that can more efficiently activate antitumor immunity...
- IDENTIFICATION OF CD8+ T CELL TARGETS ON RENAL CANCERElizabeth Jaffee; Fiscal Year: 2004..abstract_text> ..
- ALLOGENIC PANCREATIC TUMOR VACCINE CELL LINEElizabeth Jaffee; Fiscal Year: 2003..g. breast and prostate). In addition, characterization of pancreatic tumor antigens may lead to the development of recombinant vaccines that can more efficiently activate antitumor immunity. ..
- Tolerance mechanisms regulating the complete HER-2/neu CD+8 T cell repertoireELIZABETH MARION JAFFEE; Fiscal Year: 2010..Specifically, we will evaluate a number of mechanisms that may differentially regulate low versus high avidity T cells including: regulatory T cells, T cell signaling pathways, and post-transcriptional regulation. ..